Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
-8.00K | 0.00 | -13.00K | -23.00K | -42.00K | -47.00K | EBIT |
-26.48M | -14.55M | -7.10M | -4.43M | -4.04M | 3.13M | EBITDA |
-17.80M | -21.98M | -7.09M | -4.41M | -4.00M | -3.08M | Net Income Common Stockholders |
-12.84M | 22.60M | -7.10M | -4.44M | -4.10M | -2.60M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
9.10M | 5.62M | 4.49M | 2.31M | 6.06M | 9.82M | Total Assets |
9.61M | 5.93M | 4.91M | 2.44M | 6.26M | 10.61M | Total Debt |
52.00K | 267.00K | 196.00K | 195.00K | 250.00K | 363.00K | Net Debt |
-9.05M | -5.35M | -4.30M | -2.12M | -5.81M | -9.46M | Total Liabilities |
2.35M | 18.93M | 1.71M | 1.21M | 1.11M | 1.62M | Stockholders Equity |
7.26M | -13.00M | 3.20M | 1.23M | 5.16M | 8.98M |
Cash Flow | Free Cash Flow | ||||
-12.54M | -12.59M | -6.56M | -3.73M | -3.77M | -3.55M | Operating Cash Flow |
-12.49M | -12.49M | -6.56M | -3.73M | -3.77M | -3.50M | Investing Cash Flow |
-54.00K | -104.00K | 0.00 | 1.00K | -1.00K | -53.00K | Financing Cash Flow |
20.14M | 13.74M | 8.73M | 0.00 | 0.00 | 13.01M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
70 Neutral | $17.80M | 1.70 | 7.10% | ― | -0.19% | -18.41% | |
54 Neutral | $71.38M | ― | -88.36% | ― | -9.13% | 30.04% | |
54 Neutral | $5.28B | 3.29 | -45.38% | 2.80% | 16.77% | -0.08% | |
41 Neutral | $8.85M | ― | -504.16% | ― | -31.31% | 49.27% | |
38 Underperform | $21.79M | ― | -239.87% | ― | 61.97% | -6.89% | |
28 Underperform | $4.12M | ― | -694.34% | ― | ― | -94.61% | |
$3.81M | ― | -75.14% | ― | ― | ― |
On April 29, 2025, GlucoTrack, Inc. issued an investor presentation. The presentation is part of a current report on Form 8-K and is not considered filed for purposes of the Securities Exchange Act of 1934.
Spark’s Take on GCTK Stock
According to Spark, TipRanks’ AI Analyst, GCTK is a Underperform.
GlucoTrack’s overall stock score is significantly impacted by its poor financial performance, characterized by a lack of revenue and negative equity. However, positive corporate events, including strategic partnerships and clinical advancements, provide some optimism. The technical analysis and valuation further emphasize the company’s current challenges, with bearish trends and poor valuation metrics. While speculative interest might arise from recent developments, the stock remains under pressure due to financial instability.
To see Spark’s full report on GCTK stock, click here.
On April 16, 2025, Glucotrack announced its participation in the FORGETDIABETES bionic pancreas initiative, a European Union-funded project aimed at developing an automated insulin delivery system for optimal glucose control without patient intervention. This collaboration is expected to revolutionize diabetes management by integrating Glucotrack’s Continuous Blood Glucose Monitor with the bionic pancreas system, potentially transforming diabetes from a disease requiring constant attention into a more manageable lifestyle condition.
Spark’s Take on GCTK Stock
According to Spark, TipRanks’ AI Analyst, GCTK is a Underperform.
GlucoTrack’s stock score reflects significant financial and technical weaknesses, primarily due to the lack of revenue and a downward price trend. However, positive developments from recent corporate events, including strategic partnerships and clinical advancements, provide some optimism for potential future growth. The company’s current valuation is poor, but strategic moves could attract speculative interest if financial and operational hurdles are addressed.
To see Spark’s full report on GCTK stock, click here.
On April 3, 2025, Glucotrack announced a strategic agreement with OneTwo Analytics AB to enhance the analysis of clinical study data from its Continuous Blood Glucose Monitor (CBGM) using AI-driven analytics. This collaboration aims to improve insights into the CBGM’s performance and clinical value, potentially revolutionizing diabetes management by providing a more convenient and less intrusive glucose monitoring solution. The partnership is expected to deliver a comprehensive ecosystem combining blood glucose insights, risk stratification data, and patient engagement tools, thereby improving care for millions of people with diabetes.
GlucoTrack reported its financial results for 2024, highlighting a transformative year as it moved from a preclinical to a clinical stage company. The company strengthened its leadership team and secured significant funding to support its growth and clinical development. Key achievements included the successful completion of the first human clinical study of its CBGM technology and obtaining ISO certification, positioning the company for further advancements in 2025. Despite increased expenses leading to a higher net loss, GlucoTrack’s financial position was bolstered by multiple funding rounds, providing a runway for upcoming milestones.
On March 19, 2025, Glucotrack announced that it will present safety and performance data from its first-in-human trial of its continuous blood glucose monitoring (CBGM) system at the 2025 International Conference on Advanced Technologies & Treatment for Diabetes in Amsterdam. The CBGM system, which measures glucose directly from the blood without on-body wearables, is designed for long-term use and aims to offer more accurate and less intrusive glucose monitoring. This presentation marks a significant step in advancing Glucotrack’s clinical program and could potentially transform diabetes management.
On February 26, 2025, Glucotrack, Inc. announced the appointment of Dr. Guillermo Umpierrez, a leading diabetes researcher and clinician, to its Medical Advisory Board. This strategic move is expected to enhance the company’s development of its innovative Continuous Blood Glucose Monitoring (CBGM) technology, which aims to improve diabetes care by offering a less intrusive and more accurate monitoring solution. Dr. Umpierrez’s extensive experience in diabetes research and care will be instrumental as Glucotrack progresses into human clinical trials, potentially strengthening its position in the diabetes care industry and offering significant advancements for stakeholders.
On February 4, 2025, Glucotrack, Inc. entered a securities purchase agreement with institutional investors to offer and sell approximately 2.6 million shares of its common stock at $1.15 per share. The offering is expected to generate gross proceeds of approximately $3.03 million, which the company plans to use for working capital and general corporate purposes. The closing of the offering is anticipated by February 5, 2025, with Dawson James Securities, Inc. acting as the placement agent. The agreement restricts the company from issuing additional shares or entering certain transactions for 30 days following the offering’s closure, while directors and executives will adhere to a 180-day lock-up period.